Tirzepatide shows potential for disease modification in obesity-related obstructive sleep apnea beyond weight loss.

Obesity is a chronic disease affecting billions globally, significantly increasing morbidity and mortality. A major complication is Obstructive Sleep Apnea (OSA), impacting over a billion individuals worldwide, with prevalence rates up to 38% in the general population. Current OSA management often relies on mechanical positive airway pressure (PAP) therapy, which addresses symptoms but not underlying disease mechanisms. This review explores Tirzepatide, a dual GLP-1R/GIPR agonist, as a potential therapeutic beyond weight reduction for obesity-related OSA.

This review article synthesizes current evidence on Tirzepatide's therapeutic potential in obesity-related obstructive sleep apnea (OSA). The authors examined existing literature regarding Tirzepatide's mechanisms of action, clinical efficacy in obesity and type 2 diabetes, and its emerging role in improving OSA outcomes. The scope extended to evaluating whether its effects on OSA severity are solely attributable to weight loss or if additional, direct physiological mechanisms are involved, aiming to assess its capacity for disease modification.

The authors conclude that existing data strongly support Tirzepatide's significant role in reducing obstructive sleep apnea (OSA) severity. This benefit is not solely attributed to its potent weight loss effects, but also to potential direct physiological impacts on upper airway anatomy and function. Tirzepatide, as a dual GLP-1R/GIPR agonist, may influence factors such as pharyngeal muscle tone, inflammation, and fluid retention, which are critical in OSA pathophysiology.

The review highlights Tirzepatide's potential for disease modification in obesity-related OSA, moving beyond symptomatic management. While specific numerical reductions in Apnea-Hypopnea Index (AHI) or other direct OSA markers are not presented as novel findings in this review, the synthesis of existing evidence points to a substantial improvement in OSA parameters observed in clinical trials for obesity and type 2 diabetes. The authors emphasize the need for further dedicated research to definitively confirm these disease-modifying effects.